Gaucher Disease, Type 3: Clinical Trials

3 trials for Gaucher Disease, Type 3, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 recruiting, 1 unknown. 3 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 13Completed 1, Recruiting 1, Unknown 1
Phase 22Completed 1, Unknown 1

Follow Gaucher Disease, Type 3: new trials by email Literature Review of Gaucher Disease, Type 3 trials Research Report on Gaucher Disease, Type 3

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease
Low-dose CAN103, High-dose CAN103 - Gaucher Disease, Type 1, Gaucher Disease, Type 3
Phase 1 / Phase 2UnknownCANbridge (Suzhou) Bio-pharma Co., Ltd.402022-07-112022-07-27
PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)
Aldurazyme (laronidase) - MPS I, MPS II
Phase 1RecruitingUniversity of California, San Francisco102021-07-012026-03-17
Efficacy and Safety Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher Disease
velaglucerase alfa - Gaucher Disease, Type 3
Phase 1 / Phase 2CompletedShire72012-09-142021-06-11

Narrower conditions

Gaucher Disease (3)  ·  Mucopolysaccharidosis IV (1)  ·  Mucopolysaccharidosis VI (1)  ·  Mucopolysaccharidosis VII (1)  ·  Sudden Infant Death (1)  ·  Wolman Disease (1)

Broader conditions

Brain Diseases (3)  ·  Brain Diseases, Metabolic (3)  ·  Brain Diseases, Metabolic, Inborn (3)  ·  Central Nervous System Diseases (3)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3)  ·  Genetic Diseases, Inborn (3)  ·  Lipid Metabolism Disorders (3)  ·  Lipid Metabolism, Inborn Errors (3)  ·  Lipidoses (3)  ·  Lysosomal Storage Diseases (3)  ·  Lysosomal Storage Diseases, Nervous System (3)  ·  Metabolic Diseases (3)  ·  Metabolism, Inborn Errors (3)  ·  Nervous System Diseases (3)  ·  Nutritional and Metabolic Diseases (3)

Interventions

Enzyme Replacement Therapy (1)  ·  GAA protein, human (1)  ·  GALNS protein, human (1)  ·  Glucosylceramidase (1)  ·  Iduronidase (1)  ·  Sebelipase alfa (1)  ·  galsulfase (1)  ·  idursulfase (1)  ·  vestronidase alfa (1)

Sponsors

CANbridge (Suzhou) Bio-pharma Co., Ltd. (1)  ·  Shire (1)  ·  University of California, San Francisco (1)

Countries

China (1)  ·  Egypt (1)  ·  India (1)  ·  Tunisia (1)  ·  United States (1)

Top investigators

Bing Han, MD (1)  ·  Tippi MacKenzie, MD (1)

Results publications

PMID 15324318, PMID 19948615, PMID 21637107, PMID 23510062, PMID 28374935, PMID 28657663, PMID 30337566, PMID 32102934, PMID 37955580, PMID 39891377, PMID 9918480